Although research specifically on Retatrutide is limited, data from similar GLP-1 medications suggests nausea may be slightly worse during the luteal phase (days 15-28) when progesterone peaks and GI motility naturally slows
Always report any unusual symptoms, and do not stop or adjust your medication without medical advice
Any medication changes require proper medical supervision and careful dose adjustments
At the same time, i.p., i.m
The 1.7 mg and 2.4 mg doses represent the therapeutic plateau where maximum GLP-1 receptor engagement occurs, producing the most significant reductions in body weight and improvements in metabolic health markers documented in clinical trials
Read the FDAs full warning here: #GLP1 #ClinicalTrials #PatientSafety #AccessEquity #ObesityResearch #DecentralizedTrials To view or add a comment, sign in More Relevant Posts The upheaval of the Health and Human Services workforce and leadership leaves much to be desired in terms of delivery, recently retired FDA Chief Information Officer Vid Desai tells BioSpace, but the regulatory agency is evolving to be more open to much needed change
